Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment.
Capmatinib (CAP) enhances the antitumor activity of PTX in TNBC by targeting c-Met-mediated pathways and shows potential to overcome resistance and improve treatment outcomes in TNBC.